Myasthenic crisis is a life-threatening complication of myasthenia gravis. It’s when the muscles that you use to breathe get so weak that you can’t get air in and out of your lungs.

When the muscles needed for breathing are affected, a patient is said to be in myasthenic crisis. This is a life-threatening situation. Though anyone can get myasthenia gravis, those most likely ...

The Muscular Dystrophy Association (MDA)’s Kickstart program has announced receipt of both U.S. orphan drug and rare pediatric disease designations in support of work for congenital myasthenic ...

Myasthenia gravis and the Lambert–Eaton myasthenic syndrome (LEMS) are two autoimmune neuromuscular junction disorders to consider in this case. Myasthenia gravis is caused by antibodies against ...

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic ...

Truist Financial analyst Joon Lee reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse ...

One participant in the inebilizumab group died of septic shock and pneumonitis, which may have been due to acute respiratory syndrome caused by myasthenic crisis. In the placebo group, two ...

and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Receive News & Ratings for argenx Daily - ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on Catalyst Pharma (CPRX – Research Report). The associated price ...

Catalyst Pharmaceuticals ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.